Revolution Medicines(US:RVMD) 美股IPO·2026-01-09 00:22Group 1 - Merck is in discussions to acquire Revolution Medicines (RVMD) for a price range of $28 billion to $32 billion, leading to a 17.24% increase in RVMD's stock price after hours, reaching a market capitalization of approximately $24.3 billion [1] - The pharmaceutical industry is undergoing strategic expansion, with Merck's financial position being robust and its profitability strong, indicating a stable market sentiment [2] - The potential acquisition of RVMD by Merck would mark the largest deal in the pharmaceutical industry in nearly three years since Bristol-Myers Squibb's $43 billion acquisition of cancer biotech company Seagen [3] Group 2 - RVMD's RAS inhibitor portfolio is expected to peak in sales exceeding $10 billion, highlighting the potential value of the acquisition for Merck [2] - Other large pharmaceutical companies are also considering acquiring RVMD, indicating competitive interest in the company and that the deal is not yet finalized [3]